Eravacycline
- Generic Name
- Eravacycline
- Brand Names
- Xerava
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31FN4O8
- CAS Number
- 1207283-85-9
- Unique Ingredient Identifier
- 07896928ZC
- Background
Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, m...
- Indication
Eravacycline is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older .
- Associated Conditions
- Intraabdominal Infections
- Associated Therapies
- -
Therapeutic Options for CRAB
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Clinical Hospital Centre Zagreb
- Target Recruit Count
- 108
- Registration Number
- NCT06440304
Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection
- Conditions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06223100
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 55
- Registration Number
- NCT05537896
- Locations
- 🇺🇸
Aaron Cumpston, Morgantown, West Virginia, United States
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 1205
- Registration Number
- NCT03032510
Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02784704
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02135276
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02135302
- Locations
- 🇺🇸
Davita Clinical Research, Lakewood, Colorado, United States
🇺🇸New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 908
- Registration Number
- NCT01978938
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Columbus Regional Research Institute, Columbus, Ohio, United States
🇨🇿Thomayer Hospital, Department of Urology, Prague, Czechia
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 541
- Registration Number
- NCT01844856
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.